阿维菌素催化选择加氢合成伊维菌素研究

用RhCl3·3H2O和TPPDS间-(二磺化三苯基膦二钠盐),在水-有机两相催化体系中对阿维菌素选择加氢制备伊维菌素的研究,考察了反应温度(60～90℃)、氢气压力(1.0～4.0MPa)、配体浓度(2.2×10-3～5.2×10-3mol/L)、三乙胺浓度(0～8.4×10-4mol/L)、不同阳离子表面活性剂(TBAC:十四烷基二甲基苄基氯化铵;CPB:溴代十六烷基吡啶;CTAB:十六烷基三甲基溴化铵;TBAI:四丁基碘化铵)及反应时间对加氢反应活性和选择性的影响,其结果表明,在该两相体系中阿维菌素进行选择加氢是可行的,阳离子表面活性剂加入加快了反应速度,提高了反应的转化率和选择性.     

伊维菌素缓释微球片剂的体外释放评价

【目的】研究不同缓冲体系对以玉米醇溶蛋白为载体制备的具有缓释性能的伊维菌素微球片剂药物溶出速度的影响;【方法】体外模拟大鼠胃肠道环境,测定伊维菌素微球片剂在不同缓冲体系中药物溶出以及释放动力学;【结果】在0.1mol/LHCl和磷酸氢二钠-柠檬酸缓冲液(pH=2.2)中,2h药物溶出率分别为19.60±0.95%和25.62±5.17%(p>0.05);在0.1mol/LHCl 0.32%胃蛋白酶(w/v)、磷酸氢二钠-柠檬酸缓冲液(pH=2.2) 0.075%胃蛋白酶(w/v)和磷酸氢二钠-柠檬酸缓冲液(pH=2.2) 0.0375%胃蛋白酶(w/v)中,2h药物溶出率分别为62.00±3.76%、74.18±8.26%和64.61±3.20%;在含有大鼠5%胃内容物的0.1mol/LHCl体系中,IVM在2h内溶出的百分率为42.27%,然后转移到含有大鼠4%小肠内容物的PBS体系中继续溶出3h,溶出百分率为88.03%;【结论】胃蛋白酶可以加速伊维菌素从微球片剂中的溶出。     

A green alternative method for analysis of ivermectin and moxidectin in environmental water samples using automatized preconcentration previous MEEKC

Antiparasitic drugs derived from macrocyclic lactones (MLs) are widely used in livestock activities around the world. An increasing concern for local authorities is the environmental pollution as a consequence of veterinary drugs widely used in rural areas. The purpose of environmental analysis is to monitor low levels of pollutant analytes in a large number of samples. Also, due to the lipophilic characteristic of these lactones, long‐chain solvents are usually required for performing sample treatment before and during the analysis. Therefore, sensitive, specific, robust, and environmentally friendly analytical methods are still required. In this paper, a new automatized preconcentration methodology followed by microemulsion electrokinetic chromatography analysis was developed for the simultaneous separation and determination of the most used MLs, ivermectin (IVM) and moxidectin (MXD) in environmental water. XAD‐4 resin was employed as an adsorbent for the preconcentration process and ethanol was used as the eluent. In contrast to traditional analysis for IVM and MXD, in this methodology nonpolluting solvents were involved during the whole process and therefore, it could be considered as a contribution to green analytical chemistry. Under optimal experimental conditions, LOD obtained for IVM and MXD were of 3 × 10^?3 and 3.6 × 10^?3 μg/L, respectively.     

Syntheses and Bioactivity of 4″-Sulfonate-5-triphenylsilyl Avermectin B_(1a) and Ivermectin B_(1a) Derivatives

IntroductionAvermectins occuring in nature are macro-cyclic lactones with important anthelmintic,insec-ticidal and miticidal activities.Avermectins andtheir many analogues,such as ivermectins( 2 2 ,2 3-dihydroavermectin B1) and4″- epi- ( methylamino) -4″- deoxyavermectin B1benzoate[1] ,bind to verte-brates′ and invertebrates′ γ- gaminobutyric acid( GABA ) - gated and invertebrate glutamate- gatedchloride channels to increase ion conductance,thereby disrupting inhibitory or excitatory ac…     

Multi-Residue Analysis of Avermectins in Bovine Liver and Muscle by Liquid Chromatography–Fluorescence Detector

A simple multi-residue analysis method for the quantitative determination of eprinomectin, abamectin, doramectin and ivermectin in bovine tissues was developed. The tissue sample was extracted with acetonitrile, followed by clean-up on a C₁₈ solid phase extraction cartridge. The eluate was derivatised before being analyzed by HPLC coupled to a fluorescence detector. The method was validated using bovine liver and muscle fortified with the drugs at 0, 5, 10 and 50 ng g⁻¹. The mean recoveries of the four drugs were 70.31–87.11% in liver and 79.57–93.65% in muscle, with relative standard deviations below 17.84% in liver and 14.68% in muscle. The limits of detection were between 0.5 and 1.0 ng g⁻¹ and the limits of quantification were 1–2 ng g⁻¹ in bovine tissues for the four drugs.     

Syntheses and Bioactivity of 4＂-Sulfonate-5-triphenyl silyl Avermectin B1a and Ivermectin B1a Derivatives

Fourteen new derivatives of avermectin B1a, and ivermectin B1a were synthesized from C5-O-triphenyl silylavermectin B1a and ivermectin B1a (yield from 40% to 83%). Their chemical structures were characterized by means of IR. ^1H NMR, ^13C NMR and FAB-MS spectrometries. Some of them show excellent insecticidal activity.     

液相色谱-质谱法测定饲料中阿维菌素类药物

建立了饲料中阿维菌素类药物(阿维菌素、多拉菌素、埃普菌素和伊维菌素)液相色谱-质谱(LC-MS)检测法. 用乙腈提取样品中的药物, 加水稀释, 加三乙胺调节pH, 经C18固相萃取柱净化, LC-MS法测定. 结果表明, 方法平均回收率为91.3%～99.8%, RSD为2.9%～15% (n=4), 配合饲料、浓缩饲料和预混合饲料中的检出限均为10 μg/kg; 定量限均为20 μg/kg. 方法可用于饲料样品中阿维菌素类药物残留量的确证检测.     

Synthesis and greener pastures biological study of bis-thiadiazoles as potential Covid-19 drug candidates

A novel series of bis- (Abdelhamid et al., 2017, Banerjee et al., 2018, Bharanidharan et al., 2022)thiadiazoles was synthesized from the reaction of precursor dimethyl 2,2′-(1,2-diphenylethane-1,2-diylidene)-bis(hydrazine-1-carbodithioate) and hydrazonyl chlorides in ethanol under ultrasonic irradiation. Spectral tools (IR. NMR, MS, elemental analyses, molecular dynamic simulation, DFT and LUMO and HOMO) were used to elucidate the structure of the isolated products. Molecular docking for the precursor, 3 and ligands 6a-i to two COVID-19 important proteins M^pro and RdRp was compared with two approved drugs, Remdesivir and Ivermectin. The binding affinity varied between the ligands and the drugs. The highest recorded binding affinity of 6c with M^pro was (?9.2 kcal/mol), followed by 6b and 6a, (?8.9 and ?8.5 kcal/mol), respectively. The lowest recorded binding affinity was (?7.0 kcal/mol) for 6 g. In comparison, the approved drugs showed binding affinity (?7.4 and ?7.7 kcal/mol), for Remdesivir and Ivermectin, respectively, which are within the range of the binding affinity of our ligands. The binding affinity of the approved drug Ivermectin against RdRp recoded the highest (?8.6 kcal/mol), followed by 6a, 6 h, and 6i are the same have (?8.2 kcal/mol). The lowest reading was found for compound 3 ligand (?6.3 kcal/mol). On the other side, the amino acids also differed between the compounds studied in this project for both the viral proteins. The ligand 6a forms three H-bonds with Thr 319(A), Sr 255(A) and Arg 457(A), whereas Ivermectin forms three H-bonds with His 41(A), Gly143(A) and Gln 18(A) for viral M^pro. The RdRp amino acids residues could be divided into four groups based on the amino acids that interact with hydrogen or hydrophobic interactions. The first group contained 6d, 6b, 6 g, and Remdesivir with 1–4 hydrogen bonds and hydrophobic interactions 1 to 10. Group 2 is 6a and 6f exhibited 1 and 3 hydrogen bonds and 15 and 14 hydrophobic interactions. Group 3 has 6e and Ivermectin shows 4 and 3 hydrogen bonds, respectively and 11 hydrophobic interactions for both compounds. The last group contains ligands 3, 6c, 6 h, and 6i gave 1–3 hydrogen bonds and 6c and 3 recorded the highest number of hydrophobic interactions, 14 for both 6c and 6 h. Pro Tox-II estimated compounds’ activities as Hepatoxic, Carcinogenic and Mutagenic, revealing that 6f-h were inactive in all five similar to that found with Remdesivir and Ivermectin. The drug-likeness prediction was carried out by studying physicochemical properties, lipophilicity, size, polarity, insolubility, unsaturation, and flexibility. Generally, some properties of the ligands were comparable to that of the standards used in this study, Remdesivir and Ivermectin.